Skip to main content
. 2023 Sep 27;73(3):496–508. doi: 10.1136/gutjnl-2023-330748

Figure 7.

Figure 7

Graphical schematic of RPLS-associated chemosensitivity in iCCA. Heterogeneous benefit from chemotherapy is associated with tumour-induced tolerogenicity and restricted anti-tumour immunity. Pending further validation, the RPLS signature could clinically empower accurate prognostic prediction and guide treatment selection. iCCA, intrahepatic cholangiocarcinoma.